Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists

Background Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are effective treatments for obesity and type 2 diabetes, but little is known about their implications for dietary intake in routine care. Concerns have emerged that appetite suppression may reduce overall food consumption and increase the risk of nutritional inadequacy in the absence of structured dietary monitoring.Methods A mixed methods service evaluation with exploratory analysis was conducted at a single NHS general practice in Northamptonshire, UK. Fourteen adults prescribed incretin-based therapies completed dietary recalls using the validated myfood24 platform and participated in semi-structured telephone interviews. Dietary intake was assessed against UK reference nutrient intakes (%RNI), and interviews were analysed thematically to explore patient experiences of incretin therapy.Results Many participants reported energy intakes below estimated requirements, with three consuming <800 kcal/day. Intakes of several nutrients, particularly fibre, vitamin D and iron, were frequently below recommended thresholds while protein intake generally exceeded requirements. Over half the cohort had multiple nutrients simultaneously below adequacy thresholds. Qualitative findings indicated that medication-related appetite suppression often led to unrecognised reductions in food intake and that participants received limited structured nutritional guidance.Conclusion This exploratory evaluation suggests that some individuals prescribed incretin-based therapies may consume very low-energy diets and fall short of key micronutrient targets despite adequate protein intake. Larger prospective studies are needed to determine the prevalence and clinical implications of dietary inadequacy during incretin therapy and to inform appropriate nutritional monitoring strategies.

Authors

Institutions

Publication Details

Journal
BMJ Nutrition Prevention & Health
Published
2026-11-17
DOI
https://doi.org/10.1136/bmjnph-2026-001622
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists

Rajna Golubić, Ellen Fallows, Sumantra Ray, Milou Ottolini et al.
5 links
BMJ Nutrition Prevention & Health
Diabetes Treatment and Management
article

Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists

Rajna Golubić, Ellen Fallows, Sumantra Ray, Milou Ottolini, Dhanush Ammineni
article en

Abstract

Background Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are effective treatments for obesity and type 2 diabetes, but little is known about their implications for dietary intake in routine care. Concerns have emerged that appetite suppression may reduce overall food consumption and increase the risk of nutritional inadequacy in the absence of structured dietary monitoring.Methods A mixed methods service evaluation with exploratory analysis was conducted at a single NHS general practice in Northamptonshire, UK. Fourteen adults prescribed incretin-based therapies completed dietary recalls using the validated myfood24 platform and participated in semi-structured telephone interviews. Dietary intake was assessed against UK reference nutrient intakes (%RNI), and interviews were analysed thematically to explore patient experiences of incretin therapy.Results Many participants reported energy intakes below estimated requirements, with three consuming <800 kcal/day. Intakes of several nutrients, particularly fibre, vitamin D and iron, were frequently below recommended thresholds while protein intake generally exceeded requirements. Over half the cohort had multiple nutrients simultaneously below adequacy thresholds. Qualitative findings indicated that medication-related appetite suppression often led to unrecognised reductions in food intake and that participants received limited structured nutritional guidance.Conclusion This exploratory evaluation suggests that some individuals prescribed incretin-based therapies may consume very low-energy diets and fall short of key micronutrient targets despite adequate protein intake. Larger prospective studies are needed to determine the prevalence and clinical implications of dietary inadequacy during incretin therapy and to inform appropriate nutritional monitoring strategies.

BMJ Nutrition Prevention & Health
University of Ulster (GB), University of Oxford (GB), Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon